The Goldman Sachs Group Trims ICON Public (NASDAQ:ICLR) Target Price to $280.00

ICON Public (NASDAQ:ICLR) had its price objective reduced by The Goldman Sachs Group from $370.00 to $280.00 in a report released on Friday, Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other analysts have also issued reports on the company. Redburn Atlantic started coverage on ICON Public in a report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price on the stock. Barclays lowered their price target on ICON Public from $350.00 to $330.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Robert W. Baird downgraded ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price target on the stock. in a research report on Thursday. Finally, Baird R W cut ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $310.45.

ICON Public Stock Down 0.6 %

Shares of ICON Public stock opened at $220.47 on Friday. ICON Public has a 12 month low of $220.01 and a 12 month high of $347.72. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.36. The stock has a market cap of $18.19 billion, a PE ratio of 25.70, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22. The business has a fifty day simple moving average of $297.75 and a 200 day simple moving average of $310.18.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $3.10 earnings per share. Research analysts predict that ICON Public will post 14.53 EPS for the current year.

Institutional Investors Weigh In On ICON Public

A number of institutional investors have recently made changes to their positions in ICLR. Ashton Thomas Private Wealth LLC bought a new position in ICON Public during the second quarter valued at approximately $54,000. ORG Partners LLC bought a new stake in shares of ICON Public during the 2nd quarter valued at $59,000. Whittier Trust Co. of Nevada Inc. grew its stake in ICON Public by 410.8% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 152 shares in the last quarter. GAMMA Investing LLC grew its stake in ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in ICON Public by 17.4% during the first quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.